Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MPL-Adjuvanted recombinant hepatitis B vaccine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group A | EXPERIMENTAL | - |
| Group B | ACTIVE_COMPARATOR | - |
| Group C | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| MPL-Adjuvanted recombinant hepatitis B vaccine | BIOLOGICAL | Intramuscular injection, 2 or 3 doses, 2 different formulations |
| Engerix™-B | BIOLOGICAL | Intramuscular injection, 2 or 3 doses |
Inclusion Criteria: * Between 18 and 40 years old. * Written informed consent will have been obtained from the subjects. * Good physical condition as established by physical examination and history taking at the time of entry. * Female participants will avoid becoming pregnant during the study peri...
MPL-Adjuvanted recombinant hepatitis B vaccine is an investigational vaccine being studied for the prevention of Hepatitis B. It is currently in Phase 3 clinical development and is not yet approved by regulatory authorities.
MPL-Adjuvanted recombinant hepatitis B vaccine is being developed by GSK plc, a global biopharma company listed on the stock exchange under the ticker symbol GSK.
MPL-Adjuvanted recombinant hepatitis B vaccine is in Phase 3 clinical development. It is an investigational vaccine and has not been approved for use outside of clinical trials.
MPL-Adjuvanted recombinant hepatitis B vaccine has one completed Phase 3 trial, NCT00698087, which compared its safety, immunogenicity, and reactogenicity to Engerix-B in 60 healthy adults in Austria.
MPL-Adjuvanted recombinant hepatitis B vaccine is not the same as Engerix-B. It is a distinct investigational vaccine that was compared against Engerix-B as an active control in a clinical trial to evaluate its safety and immune response.